Dr. Pemmaraju on the Potential Role of Novel Therapies in MPNs

Naveen Pemmaraju, MD, discusses the potential role of novel therapies in myeloproliferative neoplasms.

Naveen Pemmaraju, MD, associate professor in the Department of Leukemia of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses the potential role of novel therapies in myeloproliferative neoplasms (MPNs).

Oftentimes, patients with MPNs are ineligible ​for, intolerant ​of, or resistant to JAK inhibitors, ​Pemmaraju says. As such, there is a growing need to identify additional therapies in the space.

To date, research is focused on 2 key areas: addi​ng novel agents ​to JAK inhibitors ​and introducing completely new agents to the armamentarium, Pemmaraju explains.

​Notably, ​this research ​may play a role in mitigating the shorter overall survival that is associated with patients ​who progress on JAK inhibitors in the frontline setting​, adds Pemmaraju.

The field awaits additional data with regard to these investigational options, concludes Pemmaraju.

Related Videos
Roger Li, MD, of Moffitt Cancer Center
Michael Deininger, MD, PhD
Shubham Pant, MD, MBBS
Kedar Kirtane, MD
Mazyar Shadman, MD, MPH
Allison Winter, MD, Department of Hematology and Medical Oncology, Cleveland Clinic
Malcolm Mattes, MD, associate professor, Section of Radiation Oncology, Rutgers Robert Wood Johnson Medical School; radiation oncologist, Rutgers Cancer Institute of New Jersey
Paolo Tarantino, MD
Aditya Bardia, MD, MPH, FASCO
Giuseppe Curigliano, MD, PhD, director, Early Drug Development Division, co-chair, Experimental Therapeutics Program, the European Institute of Oncology